Free Trial
NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

Aclaris Therapeutics logo
$1.49 -0.05 (-3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 +0.01 (+0.34%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Key Stats

Today's Range
$1.48
$1.59
50-Day Range
$1.48
$2.57
52-Week Range
$0.95
$5.17
Volume
805,468 shs
Average Volume
1.17 million shs
Market Capitalization
$160.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67
Consensus Rating
Buy

Company Overview

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Remove Ads

Aclaris Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

ACRS MarketRank™: 

Aclaris Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 604th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aclaris Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aclaris Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aclaris Therapeutics is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aclaris Therapeutics is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aclaris Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aclaris Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.02% of the float of Aclaris Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently increased by 26.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aclaris Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aclaris Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.02% of the float of Aclaris Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently increased by 26.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aclaris Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for ACRS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Aclaris Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aclaris Therapeutics' insider trading history.
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Aclaris Therapeutics initiated with an Outperform at Scotiabank
Aclaris Therapeutics files $300M mixed securities shelf
See More Headlines

ACRS Stock Analysis - Frequently Asked Questions

Aclaris Therapeutics' stock was trading at $2.48 at the beginning of the year. Since then, ACRS shares have decreased by 39.9% and is now trading at $1.49.
View the best growth stocks for 2025 here
.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03. The biotechnology company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.26% and a negative net margin of 136.65%.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/06/2024
Today
4/03/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACRS
Employees
100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$11.67
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+675.2%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-88,480,000.00
Net Margins
-136.65%
Pretax Margin
-138.00%

Debt

Sales & Book Value

Annual Sales
$18.72 million
Price / Cash Flow
N/A
Book Value
$2.22 per share
Price / Book
0.68

Miscellaneous

Free Float
66,859,000
Market Cap
$162.42 million
Optionable
Optionable
Beta
0.53

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ACRS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners